MEN1 monitoring study for people in France
Part of Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This study follows people with Multiple Endocrine Neoplasia type 1 (MEN1) over time, including those with symptoms, certain isolated hormone gland problems, and people without symptoms who have the MEN1 gene change. It may help doctors learn how MEN1 starts and progresses so care can be better timed and personalized.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of MEN1 (Multiple Endocrine Neoplasia type 1), or you are being followed because of a MEN1 gene mutation
- You currently live in France
- You may qualify if you have at least two major hormone-gland problems (parathyroid, pancreas, or pituitary), even if you do not have all three
- You may qualify if you have one known MEN1-related growth or hormone problem in any of several organs, especially if linked to the MEN1 mutation
- You may also qualify if you are a family member with a confirmed MEN1 gene mutation but no symptoms yet (the study expects symptoms may appear later)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood chemistry (metabolomics) and genetic information in people who have MEN1, especially if they are being evaluated for pancreatic neuroendocrine tumors. It may help doctors better diagnose these tumors by finding patterns in test results.
This study follows people who have Multiple Endocrine Neoplasia type 1 (MEN1), a genetic condition that can cause tumors in hormone glands. It aims to monitor symptoms and lesions over time to better understand how the condition progresses and how to manage it.
This study is testing a new blood test to see if it can help diagnose neuroendocrine tumors in people with MEN1, a genetic condition that increases the risk of these tumors. The test looks for a protein called hPG80 (progastrin) and may help doctors find tumors earlier.
This trial tests a structured nursing and education program to support people with non-metastatic breast cancer who take hormone-blocking treatment. It may help you manage side effects and stay supported during follow-up, using online questionnaires and scheduled sessions.
This trial is building a database to better understand Multiple Endocrine Neoplasia Type 1 (MEN1). If you have been diagnosed with MEN1, you may be eligible to help researchers learn more about the condition.
This study follows children and adults with medullary thyroid cancer (MTC) and/or MEN2 to better understand how the condition progresses over time. It may help doctors plan care in the future by collecting long-term health and lab information, not by giving a new treatment.
Hear when a new Multiple Endocrine Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.